What is Dihexa?
Dihexa is a synthetic compound developed by Joseph Harding and colleagues at Washington State University. It is a metabolically stabilized derivative of angiotensin IV, part of the renin-angiotensin system, and was originally investigated as a potential treatment approach for Alzheimer’s disease and cognitive decline.
Unlike nootropics primarily discussed in terms of neurotransmitter modulation, Dihexa was proposed to influence synaptic growth and connectivity. Early preclinical work reported increased dendritic-spine formation and improved performance in animal memory tasks. However, these findings do not establish cognitive benefits in humans.
Evidence warning: No published human studies have established Dihexa’s efficacy, dosing, pharmacokinetics, or safety. A foundational 2014 paper supporting the HGF/c-Met mechanism was formally retracted in April 2025 after findings of fabricated western-blot data, weakening confidence in the strongest mechanistic claims.
The retraction does not automatically invalidate every separate behavioral or animal experiment involving Dihexa, including a 2013 rat study and a 2021 APP/PS1 mouse study. It does mean that the HGF/c-Met and synaptogenesis narrative should be presented as proposed and uncertain rather than established fact.
Dihexa is not FDA approved and is not an approved prescription drug. FDA has stated that it lacks sufficient information to determine whether Dihexa acetate would cause harm when administered to humans.
Potential Dihexa Benefits
All benefits below come from cell or animal studies. No published human data demonstrates any Dihexa benefit.
Cognitive Performance in Animal Models
A 2013 rat study reported that Dihexa reversed scopolamine-induced deficits in the Morris water maze after intracerebroventricular, intraperitoneal, and oral administration. A separate 2021 APP/PS1 mouse study reported improved spatial-learning performance.
Proposed Synaptogenesis
Early laboratory work reported increased dendritic-spine and synaptic-marker activity. Because a central 2014 mechanism paper was retracted, strong claims that Dihexa reliably drives synaptogenesis through HGF/c-Met should now be treated cautiously.
Neuroinflammatory Markers
The 2021 APP/PS1 mouse study reported reduced astrocyte and microglial activation, lower IL-1β and TNF-α, and higher IL-10. These findings remain preclinical and have not been reproduced in humans.
Neuroprotection in Mice
The same APP/PS1 study reported reduced neuronal loss and improved neuronal and synaptic markers in brain tissue. This suggests possible neuroprotective activity in that model but does not establish therapeutic benefit.
What to Avoid
Do not use Dihexa if you have active cancer, a personal history of cancer, precancerous conditions, or an unresolved mass without explicit specialist guidance.
HGF/c-Met signaling is a well-established pathway in tumor growth, survival, invasion, motility, and angiogenesis, and c-Met inhibitors are used or investigated in oncology. Whether Dihexa meaningfully promotes tumorigenesis in humans is unknown. No carcinogenicity studies have been conducted.
This is a mechanistically credible safety concern, but Dihexa has not been proven to cause cancer. The magnitude of any real-world risk is unknown because appropriate toxicology and human studies do not exist.
